Hematologic Malignancies   

For patients not on study, would you consider replacing missed doses of peg with a non-asparaginase based chemotherapy?

How would the risk of VTE associated with crizotinib affect your decision? Should we consider using crizotinib in combination with brentuximab?

There are conflicting reports whether it contributes to renal insufficiency. If you do switch, what is your preferred TKI in this scenario?

What are the differences in approach to B lymphoid/myeloid and T lymphoid/myeloid MPAL?

If not, how do you choose GVHD prophylaxis regimen? Is there a preference?

E.g. would you dose-reduce or continue at same dose? Baseline ANC was in the normal range

What is the role of PD-1 inhibitors after CAR-T infusion, either as maintenance therapy or in the setting of relapsed disease? 

iPET2 and iPET4 showed Deauville 5 response. CT biopsy after 4 cycles was negative. Patient is currently scheduled for 2 additional cycles of ABVD.

Does the fact that the patient is on methotrexate alter your choice?

Do you use a cutoff of 10 cm? Do you measure the size of the largest node or measure the largest conglomerate or measure the total length of the entir...

How does graft function play into your decision making? How do you utilize post allogeneic transplant chimerism in clinical practice? Do you obta...

Do you routinely check IgG levels during therapy, if not indicated by a study protocol?

If so, what regimen do you utilize?

Are there situations in which a Deauville 3 would cause you to escalate therapy?

How does your treatment approach vary depending on the underlying predisposition?

Given the POLARIX study data presented at ASH 2021, will this replace R-CHOP as the standard of care therapy in your practice? If not, how will y...

If so, what dose and fractionation would you recommend?

How does belumosudil now fit in your approach to steroid refractory chronic graft-versus-host disease?

Are there other supportive care interventions that would otherwise be covered by hospice?

Is an LP only recommended in the setting of particular subtypes of lymphoma or symptoms of CNS disease?

Do your recommendations differ between those who receive ABVD and escalated BEACOPP? Do you recommend consultation with fertility specialists for all...

Especially with the current drug shortage of nelarabine.

Would this change with someone who has a history of thrombosis (e.g. DVT/PE, MI, CVA)? Would this change with someone who is more fit vs more frail?

Results of AHOD1331 are not yet known, but adults have started using Brentuximab upfront for high risk patients  

If given both options, which donor would one prefer: haploidentical related donor or 7/8 mismatched unrelated donor using post transplant cyclophospha...

It used to be a contraindication for G-CSF use for AML patients, but currently, several protocols include it to decrease neutropenic duration.

Would you use ALK inhibitors such as crizotinib based on recent phase II data? Are there any research efforts to combine ALK inhibitors with current ...

Do you always treat with the full 21-day treatment course, or can defibrotide be stopped if certain criteria are met sooner?

Do you prefer a cHL chemotherapy backbone or PMBL chemotherapy backbone?

Specifically, are there strategies you use to 1) empower patients to participate in decision-making and 2) reassure patients who may be skeptical?

With the new COG leukemia studies, it is difficult to interpret these results in the context of their clinical status and conventional MRD 

CT scans show omental and pelvic disease.

Would you consider “bridging” therapy with something like an HMA?

Is it at neutrophil recovery, at documentation of CR on bone marrow biopsy, or is there a different point in time?

Does acute leukemia sub-type affect your decision? 

If so, what dose would you recommend? 

At what age would you treat an early stage hodgkins lymphoma patient with ABVD + RT (adult treatment) vs OEPA x 2 or AV-PC x 3 (pediatric paradigm)?&n...

Guidelines indicate RCHOPx3 +RT as category I and RCHOP x 6 below that; long term f/u for SWOG 8736 showed similar PFS and OS. Do you have and approac...

We often see young women with favorable, early stage disease in the mediastinum who have had a complete response to chemotherapy. With current smaller...

What dose do you recommend?

After ABVE-PC X4 and Ifos/vinorelbine x 2 per AHOD 0831 (and is unable to have these sites biopsied), what dose would you treat to and what volume wou...

Are the results of AHOD0031 practice changing?

It seems that with the arms up, you get better lung blocking but with arms akimbo, you might have a lower dose to the humeral head.